Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The objective of the study was to assess the BMD of total body (BMD(TB)), lumbar spine (BMD(LS)), bone mineral apparent density lumbar spine (BMAD(LS)), lean body mass, fat mass, and fat distribution during GH treatment, with or without an additional 2 yr of GnRHa.

Why It Was Studied

GnRHa treatment is thought to have negative effects on bone mineral density (BMD) and body composition.

Who Took Part

The abstract describes 50 girls taking part.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

How the Study Was Run

The design is described as randomized.

The girls were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

This was a prospective GH trial involving short SGA adolescents (≥8 yr).

BMD and body composition were longitudinally assessed by dual-energy X-ray absorptiometry.

What Was Measured

The subject headings attached to it are Adolescent Development, Body Composition, Body Height, Bone Density, Drug Combinations, Gonadotropin-Releasing Hormone and Growth Disorders.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 50 girls.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.